Thursday, May 18, 2017

​​​​​​​Synlogic backs onto Nasdaq by merging with Mirna

​​​​​​​Synlogic has landed a Nasdaq listing and an $82 million cash pile by simultaneously pulling off a reverse merger with Mirna Therapeutics and a series C round. The activity tees up the Jose Carlos Gutierrez-Ramos, Ph.D.-helmed synthetic biology startup to push its lead candidate into the clinic in the coming months.


Cambridge, Massachusetts-based Synlogic turned to a mix of new and existing investors including Arctic Aurora LifeScience, Atlas Venture, CLI Ventures, New Enterprise Associates (NEA) and OrbiMed for the $42 million series C. That round comes 15 months after Synlogic pulled in $40 million in a series B. And, when combined with the cash Mirna has left from its failed tilt at drug development, gives the company $82 million to fuel its move into the clinic.
READ MORE Synlogic backs onto Nasdaq by merging with Mirna

G1 pitches IPO to advance lung and breast cancer candidates

G1 Therapeutics thinks it has a winner on its hands with CDK4/6 inhibitor trilaciclib and is embarking on an initial public offering to give it the resources it needs to bring it to market.

The Research Triangle Park biotech says it is hoping to raise around $115 million from the IPO, which comes a little over a year after G1 raised $47 million in a venture round on the strength of some early-stage data for its lead drug.

Going public signals G1's increasing confidence  in trilaciclib (G1T28), which is in the same class as Pfizer's Ibrance (palbociclib)—the first drug of this type to reach the market in 2015 and already a $2 billion-a-year blockbuster—and Novartis' new entrant Kisqali (ribociclib). Eli Lilly is also nipping at the CDK4/6leaders' heels with its abemaciclib prospect, due to report late-stage data shortly.
READ MORE G1 pitches IPO to advance lung and breast cancer candidates

Bayer cancer drug boards path to speedy approval at FDA

The FDA has granted priority review status to Bayer’s copanlisib, setting the PI3K inhibitor up to speed through the regulatory process in 6 months or less. Bayer secured the privileged position on the strength of data from a midphase trial in patients with non-Hodgkin lymphoma (NHL).

Landing the regulatory status means Bayer will learn whether the FDA shares its enthusiasm for copanlisib within 6 months, rather than the 10 months the agency typically takes to review drugs. The precedent set by other cancer drugs with priority review status suggests the FDA may make a decision about copanlisib in less than 6 months if it is particularly bowled over by the data.
READ FULL STORY HERE- Bayer cancer drug boards path to speedy approval at FDA

Gottlieb tells staffers FDA can help—indirectly—to cut medicine prices

New FDA Commissioner Scott Gottlieb delivered his first address to agency workers yesterday, and tackling high drug prices featured prominently in the speech.

The speech trod some territory that will be familiar to those paying attention to President Trump's pronouncements on the future of the FDA, with efforts to reduce medicine pricing and improve the efficiency at the agency sitting alongside pledges to reduce smoking rates and tackle the greatest immediate challenge" of rampant opioid abuse.


Read more here Gottlieb tells staffers FDA can help—indirectly—to cut medicine prices

Editas delays IND for Allergan-partnered CRISPR program

Editas Medicine has delayed the target date for filing an IND for its lead candidate. The setback to the Allergan-partnered CRISPR program stems from delays at a third-party manufacturer working on Leber congenital amaurosis treatment LCA10.

Cambridge, Massachusetts-based Editas had planned to file an IND for LCA10 by the end of the year. Now Editas has delayed that major moment in its short history and that of the broader CRISPR field until the middle of next year. The delay stems from a misstep in the production of a material used in the manufacture of the adeno-associated viral (AAV) vectors Editas will use to deliver its gene editing payloads.

“AAV manufacturing requires several steps to happen in perfect sequence for things to all come together. And we’re using several external contractors to perform these steps. We have to produce the input material that all comes together to then create the AAV in a cell culture systems,” Editas CTO Vic Meyer told investors.

AstraZeneca sues exec Luke Miels after his defection to GlaxoSmithKline

GlaxoSmithKline's poaching of pharma industry veteran Luke Miels from AstraZeneca in January was billed as an early win success for incoming CEO Emma Walmsley, who scrambled to replace global pharma president Abbas Hussain and other departing execs.

Fast-forward to the present, and the appointment has opened a can of worms. Bloomberg reported that Miels is currently on "gardening leave" from AZ after facing a lawsuit from his current employer alleging breach of employment.

AZ wants Miels to honor the terms of the contract he signed as executive VP of its European pharma business and has taken to the courts to try to force him to do so, according to the newswire.

Intellia moves closer to clinic with CRISPR tech

Intellia Therapeutics has taken another step toward human trials of its gene editing technology after reporting new data in animal models.

The CRISPR specialist says it has been able to show for the first time that it is able to not only achieve long-term suppression of a gene using its gene-editing CRISPR/Cas9 drug, in this case the sequence coding for serum transthyretin (TTR) protein, but also demonstrate a dose-dependent reduction in the activity of the target gene in a second animal species.

New data from studies in mice show that a previously reported 97% reduction in TTR—driven by 70% gene editing efficiency working in mouse livers—lasts for up to six months from a single dose. Meanwhile, a study in rats showed a similar dose-dependent reduction in the TTR gene, and crucially evidence of comparable activity in a second species as Intellia builds the case to move to the clinic.

Biotech pioneer and former Genzyme CEO Henri Termeer dies

The biotech industry is mourning the loss of one of the sector's founding fathers after the death of Genzyme founder Henri Termeer at the age of 71.

According to the Boston Globe, Termeer died after collapsing at his home in Marblehead, Massachusetts, on Friday night.

Termeer was at the helm of Genzyme for nearly 30 years, joining the company in 1983 and rising quickly to the role of CEO before it was acquired by Sanofi in 2011 for more than $20 billion. He is credited with not only transforming the small company into one of the world's leading biotech companies but also playing a leading role in working out how to develop a business model that opened up the market for rare and orphan disease therapies—to the benefit of patients and shareholders alike.


Biotech pioneer and former Genzyme CEO Henri Termeer dies

Thursday, May 11, 2017

Prof. Dr. M. Amjad Hossain: Make your Appointment in Hotline

Prof. Dr. M. Amjad Hossain
MBBS, MS (Ortho)
Arthoplasty and trauma surgeon
President Bangladesh Orthopaedic Society
Former Professor & Head Orthopaedic Surgeon
Dhaka Medical College & Hospital
Chief Consultant
Orthopaedic Surgery Dept
Lab Aid Arthroplasty Center
Labaid Hospital Ltd,
Dhanmondi, Dhaka-1205.
Contact number: + 8801711530611

Best Practice to make your Appointment for Prof. Dr. M Amjad Hossain. Dr. Amjad hossain is the leading leader & expert Ortho Surgery across the country. 

It is little bit difficult to get appointment to him. Currently, HOTLINE is managing all the appointment behalf of LABAID HOSPITAL LTD. 

How make Appointment

# Dial Hotline 10606 the day before you wish to make Appointment

# Start Calling from couple of Mobile phone from 10:55 am.

# Hotline number is busy always. And it may take only 2 mint for Hotline to record appointment for Dr. Amjad Hossain. Because hotline has many desk and the call automatically distribute to several Desk and many of customers service agent offer appointment at a time. 

# So if you hear the voice that number is busy now. Do not cut the line. Stay connected in the line continue. When the call finished then re-dial immediately again. 

# If you try from a single number than it will be rarely possible to make your appointment. So try from different Mobile at a same time together but not from separate place. If you try from separate places, the same appointment can be booked multiple times which will interfere the HOTLINE Database. Accidentally, if you make multiple appointment for a single patient, it is your responsibility to re-call in HOTLINE and inform them that you did.


Read More About Prof. Dr. M. Amjad Hossain



Wednesday, May 10, 2017

Orthopedic Surgeon: A Bizarre Success Story behind Prof. Dr. M Amjad Hossain


Prof. Dr. M Amjad Hossain was born in Shukdebpur, Dinajpur, Bangladesh in 1953. He was an young freedom fighter. Its sorrow that to express he was injured in the war of Liberation in 1971 (between Bangladesh & Pakistan) when he was only 19 years old. He was shot on his Femur and was cured by Dr. R. J. Garst. And from that moment, he vowed that he too would dedicate his life to saving others and influenced himself to be an Orthopedic Physician. 

Family

A proud Son of Late Abdul Baki (Father) & Al-haj Amena Khatoon (Mother)

Educational and Social Background

  1. Chirirbandar Pilot High School, Dinajpur, Bangladesh (S.S.C-1968)
  2. Dinajpur Government College, Dinajpur, Bangladesh (H.S.C-1970)
  3. Dhaka Medical College, Dhaka, Bangladesh (M.B.B.S-1972 to 1978)
  4. Dhaka Medical College, Dhaka, Bangladesh (M.S on Ortho 1983 to 1986)

Foreign Training

  • Participated in the ILLIZAROV "HANDS ON TRAINING WORKSHOP" for limb lengthening procedure at Nil Ratan Sarkar Medical College, Calcutta, India. (Nov 1992)
  • 'AO' (Association for Osteosynthesis), Basic course at Singapore (April 1994).
  • As a Travelling Fellow offered by DR. R.J GARST to different institutes of USA (SEP-OCT 1994).
  • Advanced 'AO Fellowship' Course in Institute of Orthopaedics & Traumatolgy, Catherine Hospital, Stuttgart, Germany (June-July 1995).
  • Fellowship Training in Re-Constructive Hand & Micro Surgery offered by WOC (World Orthopedic Concern) in Institute of Research and Rehabilitation for HAND (IRRH) STANLY Medical College, Madras, India (Dec-Feb:1996-1997).
  • Visiting Fellowship in Sushrut Hospital, Research Center and Post Graduate Institute of Orthopedics, Nagpur, India (Dec 1998).
  • Advanced Training Program on Replacement Surgery for Hip & Knee, Bombay Hospital & Institute of Research, Bombay, India (November 2000).
  • Ambassadorial Fellowship in Australia offered by Asia Pacific Orthopedic Association (APOA) (April 2001).
  • Next proposed Fellowship Training in Department of Orthopedic Surgery, Beth Isreal Medical Center for Knee and Shoulder Replacement and Sports Medicine, New York, U.S.A in (2002).


Service History

Service History
29/09/1978 to 16/11/1979
:
In Service Trainee, Dhaka Medical College  Hospital , Dhaka, Bangladesh
17/11/1979 to 25/06/1981
:
Medical Office ( MCH-FP ) , Parbatipur Thana Health Complex, Dinajpur
30/06/1981 to 30/06/1982
:
Medical Officer, National Institute of Traumatology and Orthopedic Rehabilitation ( Former Rehabilitation Institute & Hospital for the Disabled ) , Dhaka
01/07/1982 to 01/07/1983
:
Clinical Assistant, General Surgery, Institute for Post Graduate Medicine & Research ( IPGMR ) , Dhaka
01/07/1983 to 15/07/1986
:
M.S Orthopaedic Student.  National Institute of Traumatology and Orthopedic Rehabilitation ( Former Rehabilitation Institute & Hospital for the Disabled ) ,  Dhaka
15/07/1986 to 25/06/1989
:
Clinical Assistant ,  Orthopedic Surgery, National Institute of Traumatology and Orthopedic Rehabilitation ( Former Rehabilitation Institute & Hospital for the Disabled ) , Dhaka
25/06/1989 to 24/04/1991
:
Junior Consultant , Department of Casualty
Dhaka Medical College Hospital, Dhaka
25/04/1991 to 28/02/1994
:
Assistant Professor  of Orthopaedic Surgery  , RIHD , Dhaka
01/03/1994 to 21/11/1995
:
Associate Professor ( CC ) , Orthopedic Surgery,
National Institute of Traumatology and
Orthopedic Rehabilitation (former Rehabilitation Institute & Hospital for the Disabled), Dhaka
22/11/1995 to 25/06/1996
:
Associate Professor, Orthopedic Surgery,
MAG Osmani Medical College, Sylhet
04/07/1996 to 09/11/2001
:
Associate Professor,  Orthopedic Surgery
National Institute of Traumatology and Orthopedic Rehabilitation (former Rehabilitation , Institute & Hospital Dhaka
                                                           
21/05/2001 to 09/05/2004                                                 : Professor and Head of the Department of

 

:
Professor (CC). National Institute of Traumatology & Orthopedic Rehabilitation
Dhaka Medical College. Dhaka, Bangladesh
10/05/2004 to 24/03/2007
:
Professor & Head. Orthopedic Surgery
Dhaka Medical College. Dhaka, Bangladesh
27/03/2007 to  30/09/2007
:
Professor & Head. Orthopedic Surgery
Mymenshingh Medical College. Dhaka, Bangladesh
01/10/2007 to till date
:
Chief Consultant  & Head
Orthopedic Surgery
Lab Aid Hospital, Dhanmondi, Dhaka.

Conference Attended

  • 38th Indian Orthopedic Association Conference, Bhupal, India, (November 1993).
  • Continued Medical Education (CME) of Indian Ortho, Association Bhupal, India (November 1993).
  • XII Continued Orthopedic Education ourse (C.O.E.) on "Injuries Diseases & deformities of the foot & ankle, Calcutta, India (September 1994).
  • International symposium on Orthopedic oncology Apollo Cancer Hospital, Madras, India, (January 1997).
  • 49th Hand Surgery Conference, Cincinnati, Ohio, USA, (October 1994).
  • The Second Congress of the European Federation of National Associations for Orthopedic & Traumatology, Munich- (July 4-7, 1995).
  • ROC 8th Kolkata, India, (January 2010).
  • Visited Mumbai on 20th to 25th February 2011 as an observer for Artroplasty in Lilavati, Railway Hospital, Ambai Hospital

National & International Membership

  1. President of Bangladesh Orthopedic Society.
  2. Life Member of Society for Surgeons of Bangladesh.
  3. Life Member of West Bengal Orthopedic Association.
  4. Life Member of Indian Orthopedic Association.
  5. Life Member of Trauma Society India.
  6. Life Member of SAARC Orthopedic Association.
  7. Life Member of Aisa Pacific Orthopedic Association.
  8. Member of Indian Arthoplasty Association.
  9. "AO" Alumni Association.
  10. Member of AAOS (American Academic of Orthopedic Surgeons)
  11. Member of SICOT.
  12. Member of BJD (NAN)
  13. Secretary General of Bangladesh Arthoplasty Association.

Social Works

  1. Founder of Amana Baki Residential Model School, Chirrirbandar, Dinajpur-2001.
  2. Founder & President- Amena Baki Foundation (A Social Welfare Organization)- 2000
  3. Fonder Member of Shahid Shajahan School, Sukhdevpur, Chirrirbandar, Dinajpur- 1973.
  4. Founder Member of Sukhdevpur Hazi Kalimuddin Madrasha- 2001
  5. Health Adviser (Honorary), Bangladesh Freedom Fighter Welfare Trust sincep- 1981
  6. Elected Member of Secretarial Board, Bangladesh Muktijoddah Sangsad, Central Command Council- 2000
  7. Vice President Elected at Bangladesh Orthopedic Society- 2001, Fonder of Orthopedic Care & Research Center (OCRC), Humayun Road, Mohammadpur, Dhaka 

Freedom Fight

  1. Actively took part in the war of Liberation in 1971 (7th Sector) & had been treated in different Indian Military Hospital as an war injured Freedom Fighter.
  2. Served for the treatment of war injured & Disabled freedom fighter as honorary adviser to Bangladesh Freedom Fighter welfare Trust.
  3. EC member Central Command Council, Bangladesh Muktijodha Sangshad 1999.
  4. Member, Secotor commander's forum.

#Short story of Prof. Dr. M Amjad Hossain told himself about the moment of Freedom Fight#

In 1971, I was a young man who has just passed his intermediate exams. My father wanted me to join the army. During the tensed days of March, I was at the cantonment for my ISSB exams. The hatred of the Pakistani soldiers and their commanders towards the Bengalis and Sheikh Mujib was quite clear there. The oppression that we were under the last two decades, how the Pakistanis treated us like vermin, how they exploited us financially and politically- all these created a spark in me. After the military crackdown, it went ablaze.

After the slaughter of 25th march, my family searched for a safe haven. A large number of non-bengali Biharis lived in an around my home Chirirbandor Dinajpur, so it wasn’t safe there. The women moved to remote villages. After geting the full information for the Pakistani Army they would not allow us to live with dignity rather they will crash the Bengalis. So my father took 25 young man and cross the border for west Dinajpur. It was 3rd week of April when the exile Bangladesh Govt. has formed under the Leadership of Taj Uddin Ahmed and Syed Nazrul Islam and the guerilla war started. We reached kamarpara camp where I was trained in guerilla warfare under Prof. Abu Sayeed and Captain Anwar. I took further training in Raygonj, Panighata and Shiliguri after I was made the leader of my team. I fought in deferent places of Dinajpur District under sector 7 and carried out operations in “Boro Gram”,” New Town” and “Rudrani”.

The battle in where I was shot took place on 31st July in a village named “Bharam” in Fulbari. We were to ambush a military convoy at dawn. So we took position from the night before. But somehow our positions were betrayed and the army got air of us. They didn’t show up in the morning.  We went inside the village for food. In the mean time, with the aid of Razakars, the army had surrounded the area and caught us off guard. My fellow mate Muzaffar took the charge of covering fire while we tried to escape. Muzaffar sacrificed himself saving the whole team. I got shot in my left femur while getting back. I would have been dead if the reinforcements hadn’t arrived just in time.

Wounded, I was sent to Balurghat Hospital and then deferent Military Hospital. I was there till the historical moment of independence. I returned to Bangladesh as a free man and in 1972 I got admitted in Dhaka Medical College. I graduated from DMC in 1978 and pursued my carrier in orthopedics. As I was shot in the femur, that was somewhat an inspiration for me for taking up orthopedics as a career as well as Dr. R. J Garst, I met in early 1972 for my treatment.

I’ve also served as the health advisor of “Muktijoddha Kalyan Trust” where I have treated many of my fellow freedom fighters. The words of Dr. Ronald Joseph Garst, my mentor, will always be my motivation for the relentless service I want to render to my beloved country-“these fighters are your other family. You are one of them. Doing something for them is the next war you must fight” 


Short Overview of Prof. Dr. M Amjad Hossain


Upon completion of his graduation in Medicine in the year of 1978, Prof. Dr. M Amjad Hossain followed his professional career to orthopedics as well as successfully achieved his MS Degree from National Institue of Traumatology and Orthopaedic Rehabilitation under University of Dhaka (1986). In every sphere of his life, he has devoted his time and tried to engage and serve to the Orthopaedic department of various Institutions across the nationally and Internationally.  

With the growing development of Orthopaedic Surgery and implants devices, he has restlessly started serving on the treatment of osteoporosis particularly for the elderly population and devoted himself to make strong establishment on arthroplasty surgery in Rheumatoid, Osteporosis and Degenerative arthritis affecting and disabling patients.

 

He has achieved highly specialized foreign fellowship in the field of Joint & Hip replacement and extremely trained himself at various centres.  Prof. C.S Ranawat who is an extraordinary specialized on Orthopaedic Surgery stays in NY, USA. Prof. Ranawat also given special surgery training to Prof. Dr. M Amjad Hossain recently.

Prof. Dr. M Amjad Hossain also took part in the Liberation War of Bangladesh in 1971 (Sector 7). At that time, he served to many disabled and injured fighters who wounded by Pakistani Army. As well as he was shot on his femur. At a point, he was treated by DR. R.J. Garst and get cured. After the announcement of liberty he came back to Bangladesh freely with cured. As it was everything well that Bangladesh won the Freedom and achieved the Liberty but still from that moment Prof. Dr. M Amjad felt he will dedicate his rest of life for the people serving them who is becoming disabled by accident or any other natural disaster.
When he was in the Bed of Hospital with a severe pain of his Femur, he thought about the days ashed, he thought about the people and thought about the Orthopaedic. 

He persuade himself with lots of training on the update issues and experience exchange with the most of leading orthopedic fellows of many countries. Among them USA, Singapore, Germany, Australia and India has actively contributed a new-era of his professional excellence today.

What does Dr. M Amjad say about his success and Workplace 


Prof. Dr. M Amjad Hossain firstly thank to the #LABAID HOSPITAL LTD# situated at Dhanmondi, Dhaka, Bangladesh. He is currently #Chief Consultant# of Orthopaedic Surgery Department in LABAID HOSPITAL LTD. The answer of the question is still need to be express why does he thank to LABAID HOSPITAL. It is known to almost everyone. Although there are many many famous Hospital available in Bangladesh with International standards but it was not possible to set up an environment completely for Orthopadeic Surgeons. What it implies here an environment? 




For a highly professional Ortho Surgeon, the following things are need completely for a success on their Arthroplasty. If a Ortho surgeon get an prospective and well managed environment before going to the operating room, he/she can make success better.
  • A management Team of Implants Material 
  • An operating Theater with highly Safety & Sterile Environment
  • Nursing Staff
  • A trusted qualified vendor who always supply Implants having knowledge about "AMERICAN SOCIETY FOR TESTING AND MATERIAL (ASTM).
  • A Team for assist on operating room  
Also the following reference and knowledge should have into the team.






  • Essential requirements for non active medical devices.
  • Standard for non-active surgical implants
  • Standard for instrumentation for use in association with surgical implants
  • Standard for Joint replacement implants
  • Standard for hip joint replacement implants
  • Standard for knee joint replacement implants
  •  One step forward-two steps back: early femoral component loosening in the newer design of cemented hip replacement
  • Dynamic erosion of large implant surfaces by soft tissue in Advances in Bio materials 
  • Functional aspects of the abductor muscles of the hip
  • Forces transmitted by joints in the human body proc. Instn Mech. Engrs
  • Mechanism of fracture of the femoral prosthesis in total hip replacement Int. Orthopedic


So as I was saying, LABAID was able to provide the necessary elements with expensive implants & tools to provide Hip & Knee replacement services to the people who unexpectedly victims for it. And LABAID is committed to make this Total Hip & Knee replacement services more effective day by day following the developed countries as doing around the world and offer it to the all classes of people across the nationally and internationally. 


 Success Figures of Prof. Dr. M Amjad with LABAID


From the starting stage of Total Hip & Knee replacement in #LABAID HOSPITAL LTD# Prof. Amjad Hossain nearly Replaced over 600 Hip & Knee successfully. So, it is certainly a great achievement for a Surgeon as well as prospective credit for LABAID HOSPITAL LTD. 

As gathered info: after operation (Staring from 1st day to 1 year) the team of Orthopaedic Surgery Department always keep contact with patients and keep a storage of patient's daily, weekly, monthly, quarter yearly, half yearly & yearly report of Progress. Prof. Dr. M Amjad highly believe this all patients truck report will not only help us to best practices on Hip & Knee replacements but also it will help the next day revolutionary of Medical Science which will be benefited to the next generation and young Ortho. Professional.    

A message to the young Medical Professional by Prof. Dr. M Amjad Hossain

It is known to all that Surgery like Total Hip or Knee replacement is very tough to be success even very expensive. Dr. messages that Joint Replacement is no longer difficult to get success by a surgeon. He said it is still possible to confirm 100% success on Joint Replacement but need to follow an specialized before your start on as I did Prof. Ranawat. Prof. Dr. M Amjad trying to express it notably and advice's the young professional not to go abroad for any training or special fellow for Joint Replacement as it is worthily available in Bangladesh now. He also wish the young medical students of my countries will be able to trained them on Joint Replacement with international standard even more effectively with a very low costs and once they will be the leader of it and offer service to the population as low costs as possible. 
As the maximum people of Bangladesh are living in poverty line, so many of Patients who are seeking for joint replacement need not to feel fear. Because LABAID Hospital Ltd. always trying to offer this services as low costs as possible.

Friday, April 14, 2017

Medical Devices: Technologies and Global Markets

NEWS PROVIDED BY
http://www.reportlinker.com

Apr 12, 2017, 17:40 ET
NEW YORK, April 12, 2017 /PRNewswire/ -- Use this report to:
- Understand key market dynamics and the factors impacting the global medical device technologies market, including segments and subsegments. 
- Assess market revenues of the global medical device technology industry by segment, region and products. 
- Identify market trends, issues and factors impacting medical device technologies. 
- Gain insight into major players and their corporate profile, analyzing their market shares, core competencies and strategies in the medical device technology market.

Highlights

- The global market for medical device technologies reached $458.3 billion in 2015. The market should reach $483.5 billion in 2016 and $634.5 billion by 2021, growing at a compound annual growth rate (CAGR) of 5.6% from 2016 to 2021. 
- The North America market for medical device technologies reached $168.1 billion in 2015. The market should reach $175.6 billion in 2016 and $216.1 billion by 2021, growing at a CAGR of 4.2% from 2016 to 2021. 
- The Asia-Pacific market for medical device technologies reached $101.3 billion in 2015. The market should reach $108.9 billion in 2016 and $156.6 billion by 2021, growing at a CAGR of 7.1% from 2016 to 2021. 

INTRODUCTION

This report discusses the medical device technology industry in terms of major players' market shares, market growth and size, and opportunities for different devices and regions. The report includes forecasts for market trends and revenue through 2021. Major players, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed.

STUDY GOALS AND OBJECTIVES

The goals and objectives of the study include:
- Defining and discussing the global medical device technologies market. 
- Analyzing market structure, including segments and subsegments. 
- Estimating market revenues of the global medical device technology industry by segment, region and products. 
- Identifying market trends, issues and factors impacting medical device technologies. 
- Studying various submarkets with respect to growth drivers and inhibitors of the medical device technology market. 
- Explaining opportunities in the medical device technology market with respect to region and products. 
- Profiling major players and analyzing their market shares, core competencies and strategies in the medical device technology market. 
- Tracking alliances, joint ventures, mergers and acquisitions, new product developments, and research and development in the global medical device technology market.

MARKET DESCRIPTION

A medical device is an instrument, apparatus, implant, in vitro reagent or similar device used to diagnose, prevent or treat disease or other conditions. Several medical device technologies enhance the functions of medical devices, including highly sophisticated scanners and technologically complicated implantable products, such as artificial cochlear devices, as well as the most basic laboratory equipment.

According to estimates, there are more than 500,000 medical technologies currently available in roughly 20,000 generic groups. According to the World Health Organization (WHO), there are an estimated 1.5 million different medical devices, in more than 10,000 types of generic device groups available globally. The Global Medical Devices Nomenclature (GMDN) Agency has classified these into 16 product categories. The primary aim of any medical technology is to improve medical care, making it easier to improve the overall health of users or patients. With life spans increasing over the last few decades, the importance of better care and improved quality of life has become paramount.

SCOPE OF THE REPORT
This research report incorporates an in-depth analysis of the medical device technology market, including market estimations and trends through 2018. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report also examines recent developments and product portfolios of the major players, along with their market shares. Patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for medical device technologies.

The scope of the report extends to only those medical device technologies that generate the most global revenue. Dental device technologies and some imaging devices used in dentistry overlap with other devices already covered under the imaging device technologies segments, so they have been excluded.

INTENDED AUDIENCE


- Individuals and groups who would benefit from the content of this report include:
- Medical device manufacturers and new entrants.
- Equipment distributors, hospitals and other healthcare service providers.
- Various life sciences companies.
- Research institutes, associations and academicians.

RESEARCH METHODOLOGY
A top-down approach was taken to estimate the market size of medical device technologies. Revenues from the medical device technology market were determined through primary and secondary research, including a study of the annual reports of listed market players. Secondary research was carried out with a general search of keywords through paid sources such as Factiva and One Source, and other publicly available websites, including company websites. Estimation of micro-markets was done through primary and secondary sources, and then validated through primary sources. Forecasts were based on the analysis of market trends, market dynamics and strategies of key players. Regional estimates were determined by using secondary sources verified through primary sources.

ANALYST'S CREDENTIALS
Vijay Laxmi has more than 20 years of experience in the healthcare domain. In addition to business research and consulting, she has conducted corporate briefings for top players in a wide range of market segments. She has worked with major market research firms and handled projects for various consultancies. Her market research studies include reports on:
- Various medical device markets.
- High-growth and niche markets in healthcare and life sciences.
- Home healthcare market.
- Medical tourism.


Read the full report: http://www.reportlinker.com/p02374321-summary/view-report.html

About Reportlinker 
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com 

_________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker

Related Links